ENTERO THERAPEUTICS

Entero Therapeutics is a clinical stage biopharmaceutical company specializing in the development of targeted, orally delivered therapies for gastrointestinal (GI) diseases... Entero Therapeutics' product portfolio is built around its three proprietary technologies - latiglutenase, a potentially first-in-class oral biotherapeutic designed to break up gluten and reduce celiac disease symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist with gastrointestinal (GI) indications; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.

Also known as: Entero Therapeutics, Inc.

Primary location: Boca Raton United States